Drugs / FEZAKINUMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00434746 | Jan 2007 → Feb 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00447681 | Dec 2006 → Nov 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01941537 | Oct 2013 → Feb 2016 | atopic eczema | Rockefeller University | Completed | No outcome recorded |
| Phase 2 | NCT00883896 | Jun 2009 → Feb 2011 | rheumatoid arthritis | Pfizer | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00563524 Comparator | Dec 2007 → Jun 2010 | psoriasis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FEZAKINUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743017 ↗ |
| Known as | ILV-094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00563524 ↗ |
| Action | Inhibit | “Interleukin-22 inhibitor” CHEMBL1743017 ↗ |
| Modality | Monoclonal antibody | — CHEMBL1743017 ↗ |
| Route | Intravenous | “ILV-094 Administered IV or SC to Healthy Subjects” NCT00434746 ↗ |
| Route | Subcutaneous | “ILV-094 Administered IV or SC to Healthy Subjects” NCT00434746 ↗ |
| Target | IL22 | “Interleukin-22 inhibitor” CHEMBL1743017 ↗ |